

Dr. Öğr. Üyesi TOLGA SÜTLÜ

Web: <https://avesis.acibadem.edu.tr/Tolga.Sutlu>

Uluslararası Araştırmacı ID'leri


ScholarID: 6iDVVIUAAAAJ

ORCID: 0000-0002-7813-8734

Publons / Web Of Science ResearcherID: E-1190-2012

ScopusID: 24077626900

Yoksis Araştırmacı ID: 258642



Biyografi

Dr. Tolga Sütü received his Bachelor's Degree in Biological Sciences and Bioengineering from Sabanci University in 2004. Continuing his postgraduate education in Sweden, he received his Ph.D. in Medical Science from Karolinska Institutet in 2012 and carried out his postdoctoral work at the Center for Hematology and Regenerative Medicine at Karolinska University Hospital. Upon his return to Turkey, he worked as a research group leader at Sabanci University between 2014-2019 and later as a faculty member in the Department of Molecular Biology and Genetics at Boğaziçi University until 2023.

He has been serving as a board member at the Turkish Society of Immunology since 2016. His notable awards include Science Academy Young Scientists Award Program (BAGEP) in 2017, the METU Parlar Foundation Technology Incentive Award in 2018, the Molecular Cancer Research Association's Basic Cancer Researcher of the Year award, and the JCI International's 10 Outstanding Young Persons of Turkey award in 2019.

Eğitim Bilgileri

- I. Doktora, Karolinska Institutet (Karolinska Institute), Karolinska University Hospital Huddinge, Department of Medicine, İsveç 2007 - 2012
- II. Yüksek Lisans, Karolinska Institutet (Karolinska Institute), Stockholm Research School in Molecular Life Sciences, Stockholm Research School in Molecular Life Sciences, İsveç 2005 - 2006
- III. Lisans, Sabancı Üniversitesi, Mühendislik Ve Doğa Bilimleri Fakültesi, Biyoloji Bilimleri Ve Biyomühendislik Bölümü, Türkiye 2000 - 2004

Yabancı Diller

- I. İngilizce, C2 Ustalık

Yaptığı Tezler

- I. Doktora, Expansion and genetic modification of human natural killer cells for adoptive immunotherapy of cancer,

Araştırma Alanları

Biyoteknoloji, İmmünoloji, Genetik Mühendisliği, Kanser Moleküler Biyolojisi

Akademik Unvanlar / Görevler

- I. Dr. Öğr. Üyesi, Boğaziçi Üniversitesi, Fen-Edebiyat Fakültesi, Moleküler Biyoloji Ve Genetik Bölümü, 2019 - 2023
- II. Dr. Öğr. Üyesi, Sabancı Üniversitesi, Nanoteknoloji Uygulama Ve Araştırma Merkezi, 2014 - 2019

Verdiği Dersler

- I. Molecular and Translational Biomedicine, Yüksek Lisans, 2023 - 2024
- II. İleri Moleküler ve Hüresel Biyoloji, Yüksek Lisans, 2023 - 2024
- III. Introduction to Cell Biology, Lisans, 2021 - 2022, 2020 - 2021
- IV. Advanced Genetics, Yüksek Lisans, 2020 - 2021
- V. Special Topics: Cell and Gene Therapy, Yüksek Lisans, 2019 - 2020
- VI. Immunology, Lisans, 2020 - 2021, 2019 - 2020
- VII. Life on Earth, Lisans, 2016 - 2017

Yönetilen Tezler

- I. Sütlü T., Dissecting the crosstalk between inhibitory receptor signaling and the T cell receptor in natural killer cells, Yüksek Lisans, E.ZEYNEP(Öğrenci), 2022
- II. Sütlü T., Co-receptor mediated regulation of T cell receptor signalling in natural killer cells, Yüksek Lisans, Z.SENA(Öğrenci), 2022
- III. Sütlü T., Çetiner M. S., Development of a pseudovirus-based assay for analysis of neutralizing activity against SARS-CoV-2, Doktora, C.PAMUKCU(Öğrenci), 2021
- IV. Sütlü T., Erman M. B., Functional analysis of a novel mutation in the cd70 gene leading to primary immunodeficiency disease, Yüksek Lisans, S.BEDİR(Öğrenci), 2020
- V. Sütlü T., Yüce M., Investigating the role of coiled-coil domain containing 124 (CCDC124) in innate antiviral immune response, Yüksek Lisans, A.ERTUNGA(Öğrenci), 2019
- VI. Sütlü T., A systemic comparison of different chimeric antigen receptor (car) designs for retargeting of NK-92 cells against tumor antigens, Yüksek Lisans, E.ÇELİK(Öğrenci), 2019
- VII. Sütlü T., A novel approach in cancer immunotherapy: Natural killer cells expressing t cell receptors, Yüksek Lisans, A.PARLAR(Öğrenci), 2017
- VIII. Sütlü T., Mapping intracellular immune responses against lentiviral vectors in natural killer cells using genome scale CRISPR knockout, Yüksek Lisans, A.SARAÇ(Öğrenci), 2017
- IX. Sütlü T., Erman M. B., Intracellular immunodynamics of lentiviral gene delivery in human natural killer cells, Doktora, E.CANAN(Öğrenci), 2017

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayımlanan Makaleler

- I. **TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer**
Karahan Z. S., Aras M., Sutlu T.
TURKISH JOURNAL OF HEMATOLOGY, cilt.40, sa.1, ss.1-10, 2023 (SCI-Expanded)
- II. **Human immunodeficiency virus type 1 impairs sumoylation**
Mete B., Pekbilir E., Bilge B. N., Georgiadou P., Celik E., Sutlu T., Tabak F., Sahin U.
LIFE SCIENCE ALLIANCE, cilt.5, sa.6, 2022 (SCI-Expanded)
- III. **Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma**
Nahi H., Chrobok M., Meinke S., Gran C., Marquardt N., Afram G., Sutlu T., Gilljam M., Stellan B., Wagner A. K., et al.
CELL REPORTS MEDICINE, cilt.3, sa.2, 2022 (SCI-Expanded)
- IV. **Decline of humoral immune responses after natural SARS-CoV-2 infection can be efficiently reversed by vaccination**
ÖKTELİK F. B., YILMAZ V., GELMEZ M. Y., AKDENİZ N., Pamukcu C., Sutlu T., KÖSE M., TÜZÜN E., DENİZ G.
CANADIAN JOURNAL OF MICROBIOLOGY, cilt.68, ss.543-550, 2022 (SCI-Expanded)
- V. **Development of a pseudovirus-based assay for analysis of neutralizing activity against SARS-CoV-2 in convalescent plasma**
Aras M., Pamukcu C., Celik E., Ergun E. Z., Karahan Z. S., Turkoz G., Eren C., SİLİ U., Bilgin H., Suder I., et al.
EUROPEAN JOURNAL OF IMMUNOLOGY, ss.368, 2021 (SCI-Expanded)
- VI. **A colorimetric pseudovirus-based assay using secreted embryonic alkaline phosphatase for analysis of neutralizing activity against SARS-CoV-2**
Pamukcu C., Aras M., Celik E., Ergun E. Z., Karahan Z. S., Sutlu T.
EUROPEAN JOURNAL OF IMMUNOLOGY, ss.112, 2021 (SCI-Expanded)
- VII. **Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells**
Rossi F., Josey B., Sayitoglu E. C., Potens R., Sultu T., Duru A. D., Beljanski V.
PLOS ONE, cilt.15, sa.9, 2020 (SCI-Expanded)
- VIII. **Natural killer cells genetically modified to overexpress DNAM-1 exert enhanced antitumor responses against CD112/CD155+sarcomas and other malignancies.**
Sayitoglu E. C., Chrobok M., Georgoudaki A., Josey B. J., Hartman M., Vallabhaneni E., Herekar R., Bergeron S., Krueger R., Sutlu T., et al.
CANCER IMMUNOLOGY RESEARCH, sa.4, ss.64-65, 2020 (SCI-Expanded)
- IX. **Engineering antigen-specific natural killer cells against the melanoma-associated antigen tyrosinase via TCR gene transfer.**
Parlar A., Sayitoglu E. C., Pamukcu C., Georgoudaki A., Ozkazanc D., Aras M., Josey B., Chrobok M., Branecki S., Zahedimaram P., et al.
CANCER IMMUNOLOGY RESEARCH, sa.4, ss.49-50, 2020 (SCI-Expanded)
- X. **Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D**
Sayitoglu E. C., Georgoudaki A., Chrobok M., Ozkazanc D., Josey B. J., Arif M., Kusser K., Hartman M., Chinn T. M., Potens R., et al.
FRONTIERS IN IMMUNOLOGY, cilt.11, 2020 (SCI-Expanded)
- XI. **Myeloid maturation potentiates STAT3-mediated atypical IFN-gamma signaling and upregulation of PD-1 ligands in AML and MDS**
YÖYEN ERMİŞ D., Tunali G., Tavukcuoglu E., Horzum U., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.
SCIENTIFIC REPORTS, cilt.9, 2019 (SCI-Expanded)
- XII. **Plasmonic Selection of ssDNA Aptamers against Fibroblast Growth Factor Receptor**
KURT H., Eyupoglu A. E., Sutlu T., Budak H., Yuce M.
ACS COMBINATORIAL SCIENCE, cilt.21, sa.8, ss.578-587, 2019 (SCI-Expanded)
- XIII. **Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer**
Parlar A., Sayitoglu E. C., Ozkazanc D., Georgoudaki A., Pamukcu C., Aras M., Josey B. J., Chrobok M., Branecki S., Zahedimaram P., et al.
EUROPEAN JOURNAL OF IMMUNOLOGY, sa.8, ss.1278-1290, 2019 (SCI-Expanded)

- XIV. **Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells**
Chrobok M., Dahlberg C. I. M., Sayitoglu E. C., Beljanski V., Nahi H., Gilljam M., Stellan B., Sutlu T., Duru A. D., Alici E.
CANCERS, cilt.11, sa.1, 2019 (SCI-Expanded)
- XV. **Circulating LL37 targets plasma extracellular vesicles to immune cells and intensifies Behcet's disease severity**
Kahraman T., Gucluler G., Simsek I., Yagci F. C., Yildirim M., ÖZEN C., Dinc A., Gursel M., Ikromzoda L., Sutlu T., et al.
JOURNAL OF EXTRACELLULAR VESICLES, cilt.6, 2017 (SCI-Expanded)
- XVI. **Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma**
Duru A. D., Sutlu T., Wallblom A., Uttervall K., Lund J., Stellan B., Gahrton G., Nahi H., Alici E.
PLOS ONE, cilt.10, sa.9, 2015 (SCI-Expanded)
- XVII. **Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model**
Bestas B., Moreno P. M. D., Blomberg K. E. M., Mohammad D. K., Saleh A. F., Sutlu T., Nordin J. Z., Guterstam P., Gustafsson M. O., Kharazi S., et al.
JOURNAL OF CLINICAL INVESTIGATION, cilt.124, sa.9, ss.4067-4081, 2014 (SCI-Expanded)
- XVIII. **In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidene et al**
Sutlu T., Alici E., Gahrton G., Nahi H.
MEDICAL ONCOLOGY, cilt.30, sa.2, 2013 (SCI-Expanded)
- XIX. **Inhibition of Intracellular Antiviral Defense Mechanisms Augments Lentiviral Transduction of Human Natural Killer Cells: Implications for Gene Therapy**
Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S. E., Alici E.
HUMAN GENE THERAPY, cilt.23, sa.10, ss.1090-1100, 2012 (SCI-Expanded)
- XX. **Clinical impact of chromosomal aberrations in multiple myeloma**
Nahi H., Sutlu T., Jansson M., Alici E., Gahrton G.
JOURNAL OF INTERNAL MEDICINE, cilt.269, sa.2, ss.137-147, 2011 (SCI-Expanded)
- XXI. **Ex vivo expansion of natural killer cells: a question of function**
Sutlu T., Alici E.
CYTOTHERAPY, cilt.13, sa.6, ss.767-768, 2011 (SCI-Expanded)
- XXII. **Constitutional inv(3) in myelodysplastic syndromes**
Gahrton C., Nahi H., Jansson M., Wallblom A., Alici E., Sutlu T., Samuelsson J., Gahrton G.
LEUKEMIA RESEARCH, cilt.34, sa.12, ss.1627-1629, 2010 (SCI-Expanded)
- XXIII. **Suicide gene therapy for graft-versus-host disease**
Georgoudaki A., Sutlu T., Alici E.
IMMUNOTHERAPY, cilt.2, sa.4, ss.521-537, 2010 (SCI-Expanded)
- XXIV. **Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor**
Sutlu T., Stellan B., Gilljam M., Quezada H. C., Nahi H., Gahrton G., Alici E.
CYTOTHERAPY, cilt.12, sa.8, ss.1044-1055, 2010 (SCI-Expanded)
- XXV. **Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study**
Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., Christensson B., Guven H., Bjorkstrom N. K., Soderdahl G., et al.
IMMUNOTHERAPY, cilt.1, sa.5, ss.753-764, 2009 (SCI-Expanded)
- XXVI. **Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation**
Paul E., Sutlu T., Deneberg S., Alici E., Bjorkstrand B., Jansson M., Lerner R., Wallblom A., Gahrton G., Nahi H.
ONCOLOGY REPORTS, cilt.22, sa.1, ss.137-142, 2009 (SCI-Expanded)
- XXVII. **Natural killer cell-based immunotherapy in cancer: current insights and future prospects**
Sutlu T., Alici E.
JOURNAL OF INTERNAL MEDICINE, cilt.266, sa.2, ss.154-181, 2009 (SCI-Expanded)

- XXVIII. **The prognostic significance of 8p21 deletion in multiple myeloma**
Sutlu T., Alici E., Jansson M., Wallblom A., Dilber M. S., Gahrton G., Nahi H.
BRITISH JOURNAL OF HAEMATOLOGY, cilt.144, sa.2, ss.266-268, 2009 (SCI-Expanded)
- XXIX. **Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components**
Alici E., Sutlu T., Boejrkstrand B., Gilljam M., Stellan B., Nahi H., Quezada H. C., Gahrton G., Ljunggren H., Dilber M. S.
BLOOD, cilt.111, sa.6, ss.3155-3162, 2008 (SCI-Expanded)
- XXX. **Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model**
Alici E., Konstantinidis K. V., Sutlu T., Aints A., Gahrton G., Ljunggren H., Dilber M. S.
EXPERIMENTAL HEMATOLOGY, cilt.35, sa.12, ss.1839-1846, 2007 (SCI-Expanded)
- XXXI. **Delivery of short interfering RNA using endosomolytic cell-penetrating peptides**
Lundberg P., El-Andaloussi S., Sutlu T., Johansson H., Langel U.
FASEB JOURNAL, cilt.21, sa.11, ss.2664-2671, 2007 (SCI-Expanded)
- XXXII. **Triticum durum metallothionein - Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling**
Bilecen K., Ozturk U., Duru A., Sutlu T., Petoukhov M., Svergun D., Koch M., Sezerman U., Cakmak I., Sayers Z.
JOURNAL OF BIOLOGICAL CHEMISTRY, cilt.280, sa.14, ss.13701-13711, 2005 (SCI-Expanded)

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **STAT3-mediated atypical IFN-gamma signaling modulates the PD-1 ligands in CD11b-positive subpopulation of MDS and AML cells**
YÖYEN ERMİŞ D., Tunali G., Tavukcuoglu E., Ozkazanc D., Sutlu T., BÜYÜKAŞIK Y., ESENDAĞLI G.
17th International Congress of Immunology of the International-Union-of-Immunological-Societies (IUIS), Beijing, Çin, 19 - 23 Ekim 2019, ss.90
- II. **Identification and strategic targeting of key anti-viral defense mechanisms in Natural Killer cells**
Sayitoglu E. C., Ozkazanc D., Sarac A., Parlar A., Alici E., ERMAN M. B., Duru A. D., SÜTLÜ T.
Annual Meeting of the American-Association-of-Immunologists (AAI), Texas, Amerika Birleşik Devletleri, 4 - 08 Mayıs 2018
- III. **Engineering antigen-specific NK cells via TCR gene transfer: A novel source for adoptive immunotherapy**
Parlar A., Pamukcu C., Ozkazanc D., Aras M., Dahlberg C., Chrobok M., Zahedimaram P., Ikromzoda L., Sayitoglu E. C., Alici E., et al.
European-Society-of-Gene-and-Cell-Therapy (ESGCT) Congress, Berlin, Almanya, 01 Ocak 2017
- IV. **Adaption of NK-92 cells to serum-free culture with inherent anti-tumor response: NK-92 cells stand strong in a serum-free milieu**
Chrobok M., Dahlberg C. I. M., Sayitoglu C., Nahi H., Sarhan D., Gilljam M., Stellan B., Sutlu T., Duru A. D., Alici E.
44th Annual Meeting of the Scandinavian-Society-for-Immunology (SSI), Stockholm, İsveç, 17 - 20 Ekim 2017, ss.342
- V. **Optimized genetic modification of primary human NK cells**
Wagner A. K., Chrobok M., Hussain A., Gilljam M., Dahlberg C. I. M., Sutlu T., Duru A. D., Nahi H., Lundqvist A., Ljunggren H., et al.
44th Annual Meeting of the Scandinavian-Society-for-Immunology (SSI), Stockholm, İsveç, 17 - 20 Ekim 2017, ss.348
- VI. **Innate immune sensors restrict lentiviral gene delivery to human natural killer cells: novel perspectives on the use of viral vectors**
Sayitoglu E. C., Duru A. D., Chrobok M., Chiang C., Parlar A., Senturk G. H., Erman B., Alici E., Sutlu T.
Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy (ESGCT) and Finnish-Society-of-Gene-

Therapy (FSGT), Helsinki, Finlandiya, 17 - 20 Eylül 2015

VII. Multiple Myeloma patients with del(8)(p21) are more resistant to Bortezomib treatment

Duru A. D., Sutlu T., Wallblom A., Uttervall K., Lund J., Stellan B., Gahrton G., Nahi H., Alici E.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015

VIII. Personalized therapy for X-linked agammaglobulinemia (XLA) by oligonucleotide-induced splice-correction

Bestas B., Moreno P. M. D., Blomberg K. E. M., Mohammad D. K., Saleh A. F., Sutlu T., Nordin J. Z., Guterstam P., Kharazi S., Behlke M. A., et al.

ESGCT and NVGCT Collaborative Congress, The Hague, Hollanda, 23 - 26 Ekim 2014

IX. Enhancement of lentiviral transduction efficiency by inhibition of intracellular anti-viral defense mechanisms

Sutlu T., Nystrom S., Gilljam M., Stellan B., Applequist S. E., Alici E.

Collaborative Congress of the European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gene-Therapy, Versailles, Fransa, 25 - 29 Ekim 2012

X. RNA THERAPEUTICS IN XLA - A NOVEL STRATEGY TO REPAIR BTK MUTATIONS

Bestas B., Moreno P. M., Blomberg K. E. M., Berglof A., Gustafsson M. O., Mohammad D. K., Sutlu T., Lundin K. E., Asplund A. C., El-Andaloussi S., et al.

15th Biennial Meeting European-Society-for-Immunodeficiency (ESID), Florence, İtalya, 3 - 06 Ekim 2012, ss.165-166

XI. Expansion of NK cells for cancer immunotherapy: from process optimization to clinical evaluation

Sutlu T., Gahrton G., Alici E.

18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, İtalya, 22 - 25 Ekim 2010, ss.1416

XII. Ex vivo expanded autologous natural killer cells as a novel therapeutic approach in multiple myeloma

Alici E., Sutlu T., Bjokstrand B., Gilljam M., Stellan B., Nahi H., Quezada H. C., Gahrton G., Ljunggren H., Dilber M. S.

16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belçika, 13 - 16 Kasım 2008, ss.1183

XIII. Natural killer cells kill syngeneic myeloma cells in C57Bl/KaLwRij upon adoptive transfer

Alici E., Sutlu T., Gahrton G., Dilber S.

15th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Rotterdam, Hollanda, 27 - 30 Ekim 2007, ss.992-993

Desteklenen Projeler

- I. Sütlu T., TÜBİTAK Projesi, Hedefe Özgü Pan-Kanser Terapiler, 2021 - 2025
- II. Sütlu T., TÜBİTAK Projesi, Melanom Antijenlerine Spesifik T Hücresi Reseptörleri ile Modifiye Edilen Doğal Öldürücü Hücrelerin Kanser Aşısı Olarak Geliştirilmesi, 2020 - 2024
- III. Sütlu T., TÜBİTAK Projesi, Ülkemizde ve Dünyada Halk Sağlığını En Fazla Tehdit Eden HIV, HPV ve Influenza Kaynaklı Enfeksiyonlara Karşı Tanı Kitleri, İlaç Formülasyonları ve Aşı Geliştirilmesi, 2020 - 2023
- IV. Sütlu T., Yükseköğretim Kurumları Destekli Proje, COVID-19 konvelasan plazma vericilerinde oluşan antikor etkinliğinin belirlenmesi için psödovirüse dayalı nötralizasyon testi geliştirilmesi, 2020 - 2021
- V. Erman M. B., Sütlu T., Atılgan C., Erman B., TÜBİTAK Projesi, Protein-Protein Bağlantısını Kontrol Eden Nanobodilerin Keşfi, 2018 - 2021
- VI. Erman M. B., Sütlu T., TÜBİTAK Projesi, Development of Bevacizumab Biosimilar Drugs, 2016 - 2020
- VII. Sütlu T., TÜBİTAK Projesi, Bevacizumab Etkin Maddeli Biyobenzer Ürünün Geliştirilmesi ve Üretilmesi, 2017 - 2019
- VIII. Sütlu T., TÜBİTAK Projesi, Kanser İmmünoterapisi Hedef Moleküllerinin Keşfi İçin Hücresel Düzeyde Bir Tarama Testi, 2015 - 2018
- IX. TÜBİTAK Projesi, Viral vektörlerle gen aktarımında yeni yaklaşımlar (TÜBİTAK 2232), 2016 - 2017

- X. Stl T., TBTAK Projesi, Kanser İmmnoterapisinde Bir Nanotp Uygulamas Olarak DK Hcresi Tabanlı Eksozomlar, 2014 - 2017

Patent

- I. Stl T., Enhanced gene delivery to natural killer cells, hematopoietic stem cells and macrophages, Patent, BLM A İnsan İhtiyaçları, Buluşun Tescil No: EP3356524B1 , Standart Tescil, 2021
- II. Stl T., ERMAN M. B., Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof, Patent, BLM A İnsan İhtiyaçları, Buluşun Başvuru Numarası: PCT/US2018/012403 , Standart Tescil, 2018

Bilimsel Dergilerdeki Faaliyetler

- I. TURKISH JOURNAL OF IMMUNOLOGY, Yardımcı Editr/Blm Editr, 2021 - Devam Ediyor

Bilimsel Kuruluşlardaki yelikler / Grevler

- I. Trk İmmnoloji Derneęi, Ynetim Kurulu yesi, 2016 - Devam Ediyor , Trkiye
- II. Molekler Biyoloji Derneęi, Ynetim Kurulu yesi, 2017 - 2020, Trkiye

Bilimsel Danıřmanlıklar

- I. Acibadem Labmed, Bilimsel Projeler İin Yapılan Danıřmanlık, Acibadem Mehmet Ali Aydınlar niversitesi, Mhendislik Ve Doęa Bilimleri Fakltesi, Molekler Biyoloji Ve Genetik Blm, Trkiye, 2023 - Devam Ediyor

Kongre ve Sempozyum Katılımı Faaliyetleri

- I. 12th Annual “Meet the Experts of Transplantation and Myeloma”: EBMT and TCT, Davetli Konuşmacı, İstanbul, Trkiye, 2024
- II. 1st International Acibadem Hematoimmunology Symposium, Davetli Konuşmacı, İstanbul, Trkiye, 2024
- III. Baheşehir niversitesi LSEV Fayda Topluluęu Turuncu Gnler: Kanseri Farkındalıęı Semineri, Davetli Konuşmacı, İstanbul, Trkiye, 2024
- IV. Trk Hematoloji Derneęi, 16. Ulusal Kemik İlięi Transplantasyonu ve Hcresel Tedaviler Kongresi, Davetli Konuşmacı, Antalya, Trkiye, 2024
- V. Trkiye Romatoloji Derneęi, İmmnoromatoloji Sempozyumu 2024, Davetli Konuşmacı, Antalya, Trkiye, 2024
- VI. Gebze Teknik niversitesi Molekler Biyoloji ve Genetik Seminer Serisi, Davetli Konuşmacı, Kocaeli, Trkiye, 2023
- VII. Trk İmmnoloji Derneęi, 26. Ulusal İmmnoloji Kongresi, Davetli Konuşmacı, Ankara, Trkiye, 2023
- VIII. Cerrahpařa Romatoloji Derneęi, 2. Genetik ve İmmnoloji Kampı, Davetli Konuşmacı, İstanbul, Trkiye, 2023
- IX. Trk Hematoloji Derneęi, Hcre ve Gen Tedavilerinde Gncel Durum alıřtay: CAR T Hcre Modeli, Davetli Konuşmacı, Ankara, Trkiye, 2023

dller

- I. Stl T., Yılın Temel Kanser Arařtırmacısı, Molekler Kanser Arařtırmaları Derneęi, Eyll 2018
- II. Stl T., Teknoloji Teřvik dl, Odt Mustafa Parlar Vakfı, Eyll 2018
- III. Stl T., Bilim Akademisi Gen Bilim İnsanları dl Programı, Bilim Akademisi, Eyll 2017